William Blair Issues Positive Estimate for IPSC Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Investment analysts at William Blair upped their Q1 2025 EPS estimates for Century Therapeutics in a research report issued to clients and investors on Thursday, March 20th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.46). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Century Therapeutics’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.89) EPS.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The firm had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.67 million.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler reduced their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research note on Thursday, March 20th. Guggenheim lowered their target price on shares of Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Chardan Capital cut their price target on Century Therapeutics from $11.00 to $7.00 and set a “buy” rating for the company in a report on Monday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $5.00.

Century Therapeutics Stock Down 5.0 %

IPSC opened at $0.55 on Monday. The firm has a market cap of $47.17 million, a P/E ratio of -0.30 and a beta of 1.75. The business’s fifty day simple moving average is $0.73 and its 200 day simple moving average is $1.14. Century Therapeutics has a 52 week low of $0.52 and a 52 week high of $4.43.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds have recently modified their holdings of the stock. Casdin Capital LLC raised its holdings in shares of Century Therapeutics by 61.6% in the 4th quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock worth $5,242,000 after purchasing an additional 1,978,190 shares during the period. Millennium Management LLC raised its holdings in Century Therapeutics by 1,041.8% in the fourth quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock valued at $1,623,000 after buying an additional 1,466,415 shares during the period. Renaissance Technologies LLC lifted its position in Century Therapeutics by 146.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock valued at $1,215,000 after buying an additional 714,685 shares in the last quarter. Deutsche Bank AG grew its stake in Century Therapeutics by 890.7% during the fourth quarter. Deutsche Bank AG now owns 193,368 shares of the company’s stock worth $195,000 after buying an additional 173,849 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Century Therapeutics in the third quarter worth $284,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.